Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» non-small cell lung cancer
non-small cell lung cancer
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
BioCentury
Wed, 05/15/19 - 11:52 pm
Iovance
LN-145
cervical cancer
Takeda
TAK-788
non-small cell lung cancer
Amgen
AMG-510
Macrogenics
margetuximab
HER2-positive metastatic breast cancer
Forty Seven
FDA expands Keytruda approval for first-line NSCLC treatment
Pharmaforum
Fri, 04/12/19 - 11:26 am
Merck
Keytruda
FDA
non-small cell lung cancer
Liquid biopsy is as effective as tissue biopsy in lung cancer, study finds
BioPharma Dive
Sun, 03/3/19 - 07:01 pm
Guardant Health
liquid biopsy
non-small cell lung cancer
Guardant360
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Endpoints
Fri, 02/8/19 - 11:40 am
Regeneron
Merck
Bristol-Myers Squibb
PD-1/L1 therapy
Libtayo
Keytruda
Opdivo
non-small cell lung cancer
In Another Lung Cancer Setback, Bristol Yanks FDA App For Drug Combo
Xconomy
Thu, 01/24/19 - 10:57 am
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
FDA
AstraZeneca’s Mystic OS analysis paints tremelimumab as a dud in NSCLC
Fierce Biotech
Fri, 11/16/18 - 12:19 pm
AstraZeneca
clinical trials
tremelimumab
non-small cell lung cancer
After historic win, Lilly partner Chi-Med’s Elunate flops in lung cancer
Fierce Pharma
Fri, 11/16/18 - 12:10 pm
China MediTech
Elunate
Eli Lilly
China
non-small cell lung cancer
Investors ding Tesaro despite responses for combo in NSCLC
BioCentury
Sat, 11/10/18 - 12:44 pm
Tesaro
non-small cell lung cancer
clinical trials
TSR-042
FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC
BioCentury
Sat, 10/20/18 - 11:13 pm
Bristol-Myers Squibb
Opdivo
FDA
EMA
Yervoy
non-small cell lung cancer
Daiichi Sankyo launches phase 1 trial of DS-1205 in EGFR-mutated NSCLC
Pharmaceutical Business Review
Fri, 10/19/18 - 10:53 pm
Daiichi Sankyo
non-small cell lung cancer
DS-1205
TP Therapeutics Secures $80 Million Mezzanine Financing
CP Wire
Fri, 10/19/18 - 11:44 am
TP Therapeutics
non-small cell lung cancer
repotrectinib
Merrimack Pharma’s stock plunges (again) on its latest cancer drug trial flop
Endpoints
Fri, 10/19/18 - 09:40 am
Merrimack Pharmaceuticals
MM-121
non-small cell lung cancer
TP Therapeutics Secures $80 Million Mezzanine Financing
Fri, 10/19/18 - 09:29 am
TP Therapeutics
non-small cell lung cancer
repotrectinib
Takeda's Alunbrig Showed Superior Intracranial Results Compared to Xalkori in Ph III Trial in Non-Small Cell Lung Cancer
CP Wire
Fri, 10/19/18 - 09:19 am
Takeda
Alunbrig
Xalkori
non-small cell lung cancer
Takeda's Alunbrig Showed Superior Intracranial Results Compared to Xalkori in Ph III Trial in Non-Small Cell Lung Cancer
Fri, 10/19/18 - 09:05 am
Takeda
Alunbrig
Xalkori
non-small cell lung cancer
Pfizer nabs fast OK for a new frontline lung cancer drug as pharma giant shows off its new R&D strategy
Endpoints
Fri, 09/28/18 - 10:27 am
R&D
Pfizer
Ian Read
dacomitinib
FDA
non-small cell lung cancer
Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer
CP Wire
Tue, 09/25/18 - 11:50 am
AstraZeneca
MedImmune
Imfinzi
non-small cell lung cancer
Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer
Tue, 09/25/18 - 09:51 am
AstraZeneca
Imfinzi
non-small cell lung cancer
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
CP Wire
Tue, 09/25/18 - 09:42 am
Takeda
Alunbrig
non-small cell lung cancer
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
Tue, 09/25/18 - 09:33 am
Takeda
Alunbrig
non-small cell lung cancer
Pages
« first
‹ previous
…
6
7
8
9
10
11
12
13
14
…
next ›
last »